Elraglusib is under clinical development by Actuate Therapeutics and currently in Phase II for Myelofibrosis. According to GlobalData, Phase II drugs for Myelofibrosis have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Elraglusib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Elraglusib overview
9-ING41 is under development for the treatment of solid tumors including primary myelofibrosis, post-polycythemia vera myelofibrosis (PPV-MF), soft tissue sarcoma, salivary gland cancer, adenoid cystic carcinoma (ACC), post-essential thrombocythemia myelofibrosis (Post-ET MF), metastatic pancreatic adenocarcinoma, neuroblastoma, treatment sensitive and treatment-resistant glioblastoma (GBM), other cancers including breast cancer, renal cancer, lung cancer, ovarian cancer, esophageal cancer and pancreatic cancer, refractory hematologic malignancies, undifferentiated pleomorphic sarcoma, central nervous system tumors, prostate cancer, myxofibrosarcoma, ependymoma, angiosarcoma, rhabdomyosarcoma, spindle cell sarcoma, osteosarcoma, Ewing sarcoma, melanoma, pancreatic ductal adenocarcinoma, adult T-cell leukemia and lymphoma. The drug candidate is administered through intravenous route. The drug candidate is a small molecule and acts by targeting Glycogen synthase kinase-3 beta (GSK-3beta). It was also under development for the treatment of Alzheimer's disease and bladder cancer, Liposarcoma, leiomyosarcoma, synovial sarcoma and bone sarcoma.
Actuate Therapeutics overview
Actuate Therapeutics is a biopharmaceutical company. It focuses on the development of novel compounds for the treatment of cancer and inflammatory diseases. The company’s lead compound 9-ING-41 is under evaluation for anti-tumor activity in various vivo models to treat cancers. Actuate aims to develop anti-cancer compounds for the treatment of brain, lung, breast, and pancreatic cancers. It also conducts research for the development of compounds to treat inflammatory diseases leading to fibrosis and neurodegeneration. The company seeks to partner with academic and life science companies to license, acquire, or partner on the development of novel compounds for oncology. Actuate is headquartered in Fort Worth, Texas, the US.
For a complete picture of Elraglusib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
